Class Action Cases

Join the case to recover your losses. Click "Join this Class Action" above.

Attorneys

Rina Restaino

Brian Schall

Immutep Limited

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Immutep announced on march 13, 2026, “that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (‘efti’) in patients in 1^st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol.” The Company added, “based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility” and that “enrolment in the study will be halted and the Company will implement an orderly wind down of the study, including appropriate patient follow up and site close out in accordance with regulatory and ethical obligations.” Based on this news, Immutep’s ADRs fell by more than 82.4% on the same day.

Press Release

IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm

Los Angeles, March 20, 2026 — The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immutep Limited (“Immutep” or “the Company”) (NASDAQ: IMMP) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Immutep announced on march 13, 2026, “that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (‘efti’) in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol.” The Company added, “based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility” and that “enrolment in the study will be halted and the Company will implement an orderly wind down of the study, including appropriate patient follow up and site close out in accordance with regulatory and ethical obligations.” Based on this news, Immutep’s ADRs fell by more than 82.4% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.

310-301-3335

info@schallfirm.com

www.schallfirm.com

Cases

*
First Last
Email Address*
Phone Number **
*
Street Address City State / Province / Region ZIP / Postal Code Country
Please upload a list of your transactions or manually enter them below
Drop files here or

Accepted file types: xls, xlsx, doc, pdf, jpg, jpeg, Max. file size: 2 GB, Max. files: 5.
You may redact your account numbers from your uploaded documents. The Schall Law Firm is committed to protecting the privacy of confidential information. Your documents will be securely held in AWS S3 and will only be used as proof of your transactions in connection with this matter.
Purchases
Purchase Dates
MM slash DD slash YYYY

Number of Shares
Price Per Share

If fractional shares, please round to the nearest whole number.
Sales
Sales Dates
MM slash DD slash YYYY

Number of Shares
Price Per Share
How did you hear about this case?*
Are you a current or former employee of the company?*
- Yes
- No
Would you like to receive case and litigation updates from The Schall Law Firm via e-mail?*
- Yes
- No
If you would like to provide additional information regarding your amount of loss or your investment (i.e. type of security purchased), please do so below.
By submitting your information, you acknowledge that this form does not create an attorney-client relationship between yourself and The Schall Law Firm. Any information you submit will be maintained as confidential. The Schall Law Firm, in its sole discretion, will contact you if it requires further information from you.